News
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
Valeant Pharmaceuticals (NYSE: VRX) CEO Joe Papa has referred to the company in the past as "the turnaround opportunity of a lifetime." A key part of his turnaround strategy has been reducing the....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Why Celldex Therapeutics Stock Crumbled in October
Shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) fell by 14.7% in October, according to S&P Global Market Intelligence. The good news -- if you can call it that -- is....
3 International Stocks for Retirees
Retirees these days are living longer than ever before. That means there's a need to not only sustain your income with dividends, but also to grow your nest egg by investing in high-quality....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
Shares of AVEO Pharmaceuticals (NASDAQ: AVEO), a small-cap biopharma focused on cancer, fell 18.6% in October, according to data from S&P Global Market Intelligence. There doesn't appear to be....
The Only 3 Big Pharma Companies Growing Market Share
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company....
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the....
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a commercial-stage biopharma focused on kidney disease, fell 8.6% in October according to data from S&P Global Market Intelligence. However,....
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
Shares of Stemline Therapeutics Inc. (NASDAQ: STML), a clinical-stage biotech developing therapies that target cancer stem cells, shot up 23% in October according to data from S&P Global....
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....
3 Stocks Changing the Future of Healthcare
The healthcare sector is in the midst of an unprecedented technological boom at the moment. Despite major advancements across several medical fields, though, this innovation bonanza is, quite....
2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when....
3 Stocks to Buy for a Better Tomorrow
Buy low, and sell high. In investing, as in life, we all hope for "a better tomorrow," and one in which the decisions we make today ultimately pay off -- figuratively, and, in the case of stocks,....
True or False: Republicans Support Legalizing Marijuana?
Chances are that you'd struggle to find an industry within the U.S. that's growing at a faster and more consistent pace than legal marijuana.Colorado, one of the eight states that's legalized....
3 Biotech Stocks That Soared This Week: Are They Buys?
Halloween week produced treats instead of tricks for some biotech investors. Quite a few biotech stocks rose by double-digit percentages, with three in particular soaring close to 30% and higher....
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall....
Why This Marijuana Stock Imploded 42% in October
Medical marijuana upstart Insys Therapeutics (NASDAQ: INSY) had a ferociously frightening month, highlighted by the arrest of its founder, the setting aside of $150 million for lawsuits, and....
Why Celgene Crashed 30% in October -- and What Now?
Few industry watchers expected much out of GED-0301, yet its failure in a phase 3 study, plus anemic sales growth for one of its most important drugs, caused Celgene Corp. (NASDAQ: CELG) shares to....
Why Exact Sciences Shares Rallied 16.7% in October
After reporting third-quarter financial results that were better than expected, Exact Sciences (NASDAQ: EXAS) shares gained 16.7% in October, according to S&P Global Market Intelligence.Exact....
Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%
Shares of Corcept Therapeutics (NASDAQ: CORT), a California-based drug developer that focuses on treating severe metabolic, oncologic, and psychiatric diseases, tumbled as much as 18% during....
Why Emergent BioSolutions Inc. Jumped Higher Today
Emergent BioSolutions (NYSE: EBS) is up 11.4% at 1:00 p.m. EDT after announcing third-quarter earnings following the closing bell yesterday. It was a solid quarter for the biodefense specialist,....
Why This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss
Wall Street analysts expected Insys Therapeutics (NASDAQ: INSY) to report dismal third-quarter results. But they didn't know just how bad those results would actually be.Insys announced its....
Why Investors Are Paying a Premium for EXACT Sciences Corporation
EXACT Sciences Corporation (NASDAQ: EXAS) operates in an industry famous for cutthroat competition that strangles profitability. In this context, the stock's 300% run-up to a nosebleed-inducing....